Company Overview and News

 
SBH / Sally Beauty Holdings, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-04-10 sec.gov
SCHEDULE 13G Amendment No. 4 SALLY BEAUTY HLDGS INC COMMON STOCK Cusip #79546E104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #79546E104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 882,338 Item 6: 0 Item 7: 12,787,542 Item 8: 0 Item 9: 12,787,542 Item 11: 10.
Upvote Downvote

1
SBH / Sally Beauty Holdings, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-04-10 sec.gov
SCHEDULE 13G Amendment No. 4 SALLY BEAUTY HLDGS INC COMMON STOCK Cusip #79546E104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #79546E104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 882,338 Item 6: 0 Item 7: 12,787,542 Item 8: 0 Item 9: 12,787,542 Item 11: 10.
Upvote Downvote

 
Big 5 Sporting (BGFV) Rallies Despite Sales Woes: Here's Why

2018-04-06 zacks
Big 5 Sporting Goods Inc. (BGFV - Free Report) stock continues its bull run despite reporting lower-than-anticipated sales results for fourth-quarter fiscal 2017 while providing a soft outlook. The sales decline stemmed from an extremely challenging performance in December. Sales in December were largely hurt by nearly 50% decrease in core winter-product categories due to warmer-than-normal and dry weather conditions in most of its markets.
Upvote Downvote

 
SBH / Sally Beauty Holdings, Inc. FORM 8-K (Current Report)

2018-04-04 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Hibbett (HIBB) Jumps 15% in 3 Months: What's Aiding Growth?

2018-04-03 zacks
Hibbett Sports Inc. (HIBB - Free Report) is climbing up the chart, thanks to its robust earnings trend in recent quarters. Though the company reported a mixed fourth-quarter fiscal 2018, its earnings beat trend remained intact. This marked its fourth straight bottom-line beat. Further, sales were in line and improved year over year, backed by gains in the apparel business driven by strong e-commerce growth, favorable weather and focus on sportswear.
Upvote Downvote

 
Should Value Investors Pick Sally Beauty (SBH) Stock?

2018-03-12 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Upvote Downvote

2
Top 10 Stocks Under $20

2018-03-02 investorplace
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
Upvote Downvote

 
A Turnaround Story Failing To Produce Profits

2018-02-28 seekingalpha
Too often, during the turnaround, investors overlook issues and send shares higher regardless of signs that the turnaround is not working as expected.
Upvote Downvote

 
Big 5 (BGFV) Falls 8% Despite Narrower-Than-Expected Q4 Loss

2018-02-28 zacks
Big 5 Sporting Goods Corporation (BGFV - Free Report) posted narrower-than-expected loss in the fourth quarter. However, sales missed the Zacks Consensus Estimate for the third straight quarter. Moreover, results declined year over year. Also, management issued weak guidance for the first quarter of 2018. Consequently, shares of this sporting goods retailer fell 7.6% in the after-hours trading. In the past three months, the stock has lost 19.
Upvote Downvote

 
Hibbett (HIBB) Falls Despite Strong Q4 Preliminary Results

2018-02-27 zacks
Hibbett Sports, Inc. (HIBB - Free Report) announced preliminary results for fourth-quarter fiscal 2018, wherein sales outpaced the Zacks Consensus Estimate. Despite the better-than-expected results, shares of the company fell 2.2% yesterday. The company reported fourth-quarter net sales of $266.7 million that improved 8% year over year, including $13.5 million for the 53rd week. The metric has also outpaced the consensus estimate of $257 million.
Upvote Downvote

 
Zacks.com highlights: Sally Beauty Holdings, HCA Healthcare, MEDNAX, Cimpress N.V. and FTI Consulting

2018-02-27 zacks
Chicago, IL – Feb 27, 2018 - Stocks in this week’s article include: Sally Beauty Holdings, Inc.(SBH - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) , MEDNAX, Inc. (MD - Free Report) , Cimpress N.V. (CMPR - Free Report) and FTI Consulting, Inc. (FCN - Free Report) .
Upvote Downvote

 
Forget Market Volatility With These 5 Low-Beta Stocks

2018-02-26 zacks
The most common strategy is to invest in risky stocks with the hope of lucrative returns. The strategy works well only when the market is bullish, but investors should prepare mentally for the opposite scenario.
Upvote Downvote

 
Zacks Value Investor Highlights: Shake Shack, Potbelly, Allstate, PACCAR and Sally Beauty

2018-02-23 zacks
Chicago, IL – February 23, 2017 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Upvote Downvote

 
Help! My Stock is Stuck in No Man's Land

2018-02-22 zacks
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service, shares some of her top value investing tips and stock picks.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 79546E104